Type 1 Diabetes Clinical Trial
— REDBULLOfficial title:
Effects of Acute Intake of Caffeine Enhanced Energy Drinks on Blood Glucose, Some Physiological Parameters and Cognitive Performance in Patients With Type 1 Diabetes
Verified date | March 2013 |
Source | The Royal Bournemouth Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Research Ethics Committee |
Study type | Interventional |
The aim of this pilot study is to determine the impact of caffeine-enhanced energy drinks on
blood glucose excursion on heart rate, blood pressure, cardiac output and cognitive
performance in patients with type 1 diabetes.
Knowledge acquired may inform a wider study of the impact of these drinks.
This is a randomised, cross over blinded study in which all participants will participate in
the 3 arms of the study.
The study will consist of 3 phases, each lasting 3 days. A different study drink will be
administered during each phase. There will be an initial screening visit and a pre- study
visit before each study phase. Each participant will make 10 visits to the research centre.
There will be a week wash out period between each study phase. Prior to each study phase,
there will be a 3 day caffeine and alcohol abstinence run-in period.
Study drinks will be matched for taste and volume (as far as possible) and will be
administered by the use of opaque cups, lids and straws to enable double-blind randomisation
for both researcher and participants. Administration of the study drink to participants will
be based on Latin squares to provide a balanced treatment order.
During the 3 days study period; participants will be required to abstain from all other
caffeine containing beverages or confectioneries.
The secondary aim is to determine if tolerance to cardiovascular effects of
caffeine-enhanced energy drinks is developed following acute short term ingestion.
Status | Completed |
Enrollment | 20 |
Est. completion date | July 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male and female adults aged =18 years - Confirmed diagnosis of Type 1 diabetes of more than one year duration - Participants who use multiple daily injections of basal and meal-time analogue insulin. - Ability to perform daily finger stick measurements of blood glucose levels - Adequate contraceptive control - Provision of informed consent Exclusion Criteria: - Hypoglycaemia unawareness - Coronary heart disease - Cardiac arrhythmia - Structural heart lesions, - Autonomic neuropathy - Psychiatry illness, - Epilepsy - Migraine - Caffeine intolerance - Unable to provide informed consent |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust | Bournemouth | Dorset |
Lead Sponsor | Collaborator |
---|---|
The Royal Bournemouth Hospital |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in blood glucose level in all patients as a measure of tolerability | Day 1, Day 2 and Day 3 | No | |
Secondary | The effects on certain mood states, e.g. energetic arousal, tense arousal and hedonic tone following the consumption of caffeinated energy drinks in comparison with caffeine free glucose in patients with type 1 diabetes | Day 1, day 2 and day 3 | No | |
Secondary | Changes in reaction time and digit symbol substitution test score | Day 1, day 2 and day 3 | No | |
Secondary | Changes in heart rate, systolic and diastolic blood pressure in all patients. | Day 1, day 2 and day 3 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |